We are live on ! Find out more
RDHL

Redhill Biopharma
RDHL

21 hedge funds and large institutions have $27.3M invested in Redhill Biopharma in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more capital invested

Capital invested by funds: $21.2M → $27.3M (+$6.09M)

5% less funds holding

Funds holding: 22 → 21 (-1)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
21
Holders Change
-1
Holders Change %
-4.55%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BHB
Bank Hapoalim BM
Israel
+$1.43M
2
DADC
D.A. Davidson & Co
Montana
+$378K
3
FAM
Fred Alger Management
New York
+$83.9K
4
Morgan Stanley
Morgan Stanley
New York
+$69.9K
5
Deutsche Bank
Deutsche Bank
Germany
+$42K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.17M
2
BC
Broadfin Capital
New York
-$280K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$228K
4
AIM
Acrospire Investment Management
Illinois
-$14K
5
PVH
Psagot Value Holdings
Israel
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$9.96M -$280K -20 -3%
O
2
OrbiMed
New York
$7.85M – – –
MMH
3
Menora Mivtachim Holdings
Israel
$3.42M – – –
BHB
4
Bank Hapoalim BM
Israel
$2.05M +$1.43M +102 +222%
CS
5
Candriam SCA
Luxembourg
$992K – – –
SM
6
Sabby Management
Florida
$888K -$1.17M -84 -57%
ISL
7
Ingalls & Snyder LLC
New York
$577K – – –
DADC
8
D.A. Davidson & Co
Montana
$368K +$378K +27 New
FAM
9
Fred Alger Management
New York
$299K +$83.9K +6 +38%
FM
10
Family Management
New York
$229K – – –
OC
11
Oppenheimer & Co
New York
$180K – – –
VanEck Associates
12
VanEck Associates
New York
$134K – – –
Morgan Stanley
13
Morgan Stanley
New York
$89K +$69.9K +5 +500%
PVH
14
Psagot Value Holdings
Israel
$51K -$14K -1 -20%
Deutsche Bank
15
Deutsche Bank
Germany
$44K +$42K +3 New
MMG
16
Monetary Management Group
Missouri
$42K – – –
UBS Group
17
UBS Group
Switzerland
$28K – – –
Wells Fargo
18
Wells Fargo
California
$27K -$14K -1 -33%
Bank of America
19
Bank of America
North Carolina
$14K – – –
Creative Planning
20
Creative Planning
Kansas
$14K – – –
WA
21
WFG Advisors
Texas
$10K – – –
AIM
22
Acrospire Investment Management
Illinois
$6K -$14K -1 Closed
TWA
23
TCI Wealth Advisors
Arizona
$4K – – –
TRCT
24
Tower Research Capital (TRC)
New York
$1K -$14K -1 Closed
MTIP
25
Magee Thomson Investment Partners
California
$1K – – –
1
2

RDHL Hedge Fund Activity: Q3 2016 in Review

21 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q3 2016, worth a combined $27.3M — up 29% from $21.2M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of RDHL and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.

The largest buyer was Bank Hapoalim BM, adding an estimated $1.43M. The largest seller was Sabby Management, cutting an estimated $1.17M.

  • 21 institutional investors held Redhill Biopharma (RDHL) as of Q3 2016, down from 22 in Q2 2016.
  • Funds reported $27.3M of Redhill Biopharma stock for Q3 2016, up 29% quarter-over-quarter.
  • 2 funds opened new Redhill Biopharma positions in Q3 2016 and 3 closed out, a net change of -1 holder.
  • The largest Redhill Biopharma buyer in Q3 2016 was Bank Hapoalim BM, an estimated $1.43M added.
  • The largest Redhill Biopharma seller in Q3 2016 was Sabby Management, an estimated $1.17M sold.

Based on aggregated 13F filings for Q3 2016.